DSM's $1.1B Martek Acquisition Comes With Potential IP Expirations
This article was originally published in The Tan Sheet
Executive Summary
Dutch ingredients giant Royal DSM N.V. incurs no incremental risk in acquiring Martek Biosciences despite the looming expiration dates for Martek's intellectual property, according to a market analyst.
You may also be interested in...
People In Brief
Erykman joins DSM as executive VP
People In Brief
Erykman joins DSM as executive VP
In Brief
Prestige Brands gains from acquisitions